There is great news for parents suffering the harrowing ordeal of their child needing a bone marrow transplant. The announcement came from Osiris Therapeutics Inc. (NASDAQ: OSIR) on Friday that Health Canada has approved its groundbreaking stem cell therapy Prochymal® (remestemcel-L). The drug can be used to treat children with acute graft-vs-host disease. (GvHD). The decision is a historic one ...
